ORIC Pharmaceuticals Reports Incentive Grants Pursuant to Nasdaq Listing Rule 5635(c)(4) Page 1

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 6, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical-stage oncology company focused on developing treatments to address mechanisms of therapy resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted an aggregate of 173,200 nonqualified stock options and 28,900 restricted stock units to three new non-executive employees who will begin employment with ORIC in August 2024.

These incentive awards were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to the continued employment or service of the recipient through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the grant date. Twenty-five percent (25%) of the shares subject to the stock options will vest on one (1) anniversary of the grant date, with one thirty-sixth (1/36^th) of the remaining shares, each of which vests after one month. One third (1/3^rd) of the Restricted Stock Units will vest on each of the first three anniversaries of the grant date. The incentive awards are subject to the terms and conditions of the applicable stock option and Restricted Stock Unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.